This “Clear Cell Sarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Clear Cell Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Clear Cell Sarcoma Understanding
Clear cell sarcoma of soft tissue (CCSST) is an exceedingly rare tumor that originates from neural crest cells and is histologically characterized by clear cells that contain accumulated glycogen. CCS tumors occur most often in the arms, legs, feet, and hands. But, CCS can grow throughout the torso, including the stomach and intestines. CCS has also been found in the genitals and head. Clear cell sarcoma tumors tend to grow attached to tendons in the limbs, especially in the feet and hands. They sometimes develop in the gastrointestinal tract, attached with the bottom layers of the skin, and in locations throughout the torso. Clear cell sarcoma is slightly more common in females than in males and can occur at all age, the mean age at the time of diagnosis is approximately 25 years. A diagnosis of Clear Cell Sarcoma is made based upon a thorough clinical evaluation and pathological evaluation. Clear cell sarcoma tumors are often imaged by an MRI and CT scan. Biopsy is done to check, if the tumor is Clear Cell Sarcoma. Genetic testing confirm the diagnosis of Clear Cell Sarcoma. Therapies that are used to treat individuals with Clear Cell Sarcoma includes surgery, radiation therapy, chemotherapy and targeted therapy. Two FDA approved chemotherapies used in the management of soft tissue sarcomas are ifosfamide and doxorubicin.
"Clear Cell Sarcoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Clear Cell Sarcoma pipeline landscape is provided which includes the disease overview and Clear Cell Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Clear Cell Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Clear Cell Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Clear Cell Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Clear Cell Sarcoma.
This segment of the Clear Cell Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TSR-042 is an investigational Programmed cell death-1 receptor antagonists. It is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with clear cell sarcoma.
This segment of the report provides insights about the different Clear Cell Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Clear Cell Sarcoma. The companies which have their Clear Cell Sarcoma drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Clear Cell Sarcoma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Clear Cell Sarcoma drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Clear Cell Sarcoma Understanding
Clear Cell Sarcoma: Overview
Clear cell sarcoma of soft tissue (CCSST) is an exceedingly rare tumor that originates from neural crest cells and is histologically characterized by clear cells that contain accumulated glycogen. CCS tumors occur most often in the arms, legs, feet, and hands. But, CCS can grow throughout the torso, including the stomach and intestines. CCS has also been found in the genitals and head. Clear cell sarcoma tumors tend to grow attached to tendons in the limbs, especially in the feet and hands. They sometimes develop in the gastrointestinal tract, attached with the bottom layers of the skin, and in locations throughout the torso. Clear cell sarcoma is slightly more common in females than in males and can occur at all age, the mean age at the time of diagnosis is approximately 25 years. A diagnosis of Clear Cell Sarcoma is made based upon a thorough clinical evaluation and pathological evaluation. Clear cell sarcoma tumors are often imaged by an MRI and CT scan. Biopsy is done to check, if the tumor is Clear Cell Sarcoma. Genetic testing confirm the diagnosis of Clear Cell Sarcoma. Therapies that are used to treat individuals with Clear Cell Sarcoma includes surgery, radiation therapy, chemotherapy and targeted therapy. Two FDA approved chemotherapies used in the management of soft tissue sarcomas are ifosfamide and doxorubicin.
"Clear Cell Sarcoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Clear Cell Sarcoma pipeline landscape is provided which includes the disease overview and Clear Cell Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Clear Cell Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Clear Cell Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Clear Cell Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Clear Cell Sarcoma.
Clear Cell Sarcoma Emerging Drugs Chapters
This segment of the Clear Cell Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Clear Cell Sarcoma Emerging Drugs
TSR-042: GlaxoSmithKline
TSR-042 is an investigational Programmed cell death-1 receptor antagonists. It is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with clear cell sarcoma.
Clear Cell Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Clear Cell Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Clear Cell Sarcoma
There are approx. 5+ key companies which are developing the therapies for Clear Cell Sarcoma. The companies which have their Clear Cell Sarcoma drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Clear Cell Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Clear Cell Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Clear Cell Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Clear Cell Sarcoma drugs.
Clear Cell Sarcoma Report Insights
- Clear Cell Sarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Clear Cell Sarcoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Clear Cell Sarcoma drugs?
- How many Clear Cell Sarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Clear Cell Sarcoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Clear Cell Sarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Clear Cell Sarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Clear Cell Sarcoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
TSR-042: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I/II)
- Comparative Analysis
CPI-613: Rafael Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Clear Cell Sarcoma Key Companies
Clear Cell Sarcoma Key Products
Clear Cell Sarcoma- Unmet Needs
Clear Cell Sarcoma- Market Drivers and Barriers
Clear Cell Sarcoma- Future Perspectives and Conclusion
Clear Cell Sarcoma Analyst Views
Clear Cell Sarcoma Key Companies
AppendixList of Tables
Table 1 Total Products for Clear Cell Sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Clear Cell Sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- NantPharma, LLC
- Rafael Pharmaceuticals
- GlaxoSmithKline
- Pfizer
- Bristol Myers Squibb
